Cargando…

TIME TO EXPAND THE USE OF CASIRIVIMAB/IMDEVIMAB MONOCLONAL ANTIBODY THERAPY? A CASE OF COMPASSIONATE USE IN SEVERE COVID-19 PNEUMONIA

Detalles Bibliográficos
Autores principales:	AHMED, MUBASHIR AYAZ, HOSSAIN ESHAN, SHAYET, HUSSEIN, SAMI, SUN, CHENYU, SANKARAN RAJAGOPALAN, KAMALNATH, HUSSEIN, KHALID
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:	Chest Infection
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549007/ http://dx.doi.org/10.1016/j.chest.2022.08.262

Ejemplares similares

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

ELDERLY PERSON WITH COVID-19 AND SEVERE ARDS WITH PROLONGED ACTIVE VIRAL REPLICATION AND DOUBLE RESURGENCE OF CYTOKINE STORM TREATED WITH SOTROVIMAB AND CASIRIVIMAB/IMDEVIMAB
por: SIRITHANAKUL, KASEM
Publicado: (2022)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19
por: Ruggeri, Matteo, et al.
Publicado: (2023)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022)

CHALLENGES IN DIAGNOSIS AND MANAGEMENT OF EVALI IN THE COVID-19 ERA: A SYSTEMATIC REVIEW
por: AYAZ AHMED, MUBASHIR, et al.
Publicado: (2021)

Reverse Takotsubo Cardiomyopathy After Casirivimab-Imdevimab Therapy in a Patient with COVID-19: A Case Report
por: Salehin, Salman, et al.
Publicado: (2022)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes
por: O'Brien, Meagan P., et al.
Publicado: (2021)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

A CASE OF PROLONGED SARS-COV-2 INFECTION IN AN IMMUNOSUPPRESSED PATIENT WHO RESPONDED TO TREATMENT WITH REMDESIVIR AND MONOCLONAL ANTIBODIES
por: SINANAN, VIVEK
Publicado: (2022)

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
por: Phan, Alexander T, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
por: Simpson, Michelle, et al.
Publicado: (2022)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19
por: Zitek, Tony, et al.
Publicado: (2022)

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

RISK FACTORS FOR IN-HOSPITAL MORTALITY AMONG ADULTS HOSPITALIZED WITH COVID-19: A CROSS-SECTIONAL STUDY FROM JORDAN
por: AL-MISTAREHI, ABDEL-HAMEED, et al.
Publicado: (2022)

1157. The Clinical Impact of Casirivimab–Imdevimab Monoclonal Antibody Therapy (CIMAT) in COVID-19 patients: A real-world insight from India.
por: Kochuparambil, Jose J, et al.
Publicado: (2022)

Bamlanivimab/casirivimab/imdevimab: Burning, eye pain and lack of efficacy following off-label use: 8 case reports
Publicado: (2022)

Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database
por: Hussein, Mohamed, et al.
Publicado: (2022)

ACTIVE TB AFTER THE USE OF TOCILIZUMAB FOR COVID-19 INFECTION
por: NOH, SUNGRYONG, et al.
Publicado: (2021)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan
por: Komagamine, Junpei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3feokl50kitu6idv7rh1j5692j